Pro­men­tis rais­es $26M for glu­ta­mater­gic drug R&D; CARB-X of­fers up to $48M for fight­ing drug-re­sis­tant bac­te­ria

→  Mil­wau­kee-based Pro­men­tis Phar­ma­ceu­ti­cals has raised $26 mil­lion in a C round. Or­biMed, F-Prime Cap­i­tal Part­ners (for­mer­ly Fi­deli­ty Bio­sciences) and Ais­ling Cap­i­tal led the round. Ex­ist­ing in­vestors, in­clud­ing Black Pearl GmbH, the Gold­en An­gel Net­work and in­di­vid­ual in­vestors, al­so par­tic­i­pat­ed. The biotech is push­ing SXC-2023 — a small mol­e­cule de­signed to en­gage Sys­tem Xc-, a CNS tar­get ad­dress­ing glu­ta­mater­gic dys­func­tion and ox­ida­tive stress — in­to Phase II. The biotech has raised a to­tal of $31 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER